AngioDynamics posts slight sales growth, net loss in Q3

2020 02 06 18 18 1550 Business Financial Results 400

Higher revenues from its Auryon and AngioVac platforms helped interventional technology developer AngioDynamics to achieve a 2% increase in net sales in its 2021 fiscal third quarter despite ongoing headwinds from the COVID-19 pandemic.

For the period (end-February 28), AngioDynamics had net sales of $71.2 million, up from $69.8 million from the same quarter a year ago. The company had a third-quarter net loss of $3.5 million, compared with a net loss of $5.7 million last year.

In other developments, AngioDynamics increased its guidance for the 2021 fiscal year. The firm said it now expects to produce net sales between $285 million to $288 million, up from previous projections of $278 million to $284 million.

Page 1 of 3453
Next Page